The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1668
ISSUE1668
January 23, 2023
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
January 23, 2023 (Issue: 1668)
The FDA has approved Ryaltris (Hikma), a fixed-dose
combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase,
and generics) and the corticosteroid mometasone
furoate (Nasonex 24 HR Allergy, and generics),...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.